Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy

Metabolic Syndrome and Related Disorders

Volumn 2, Issue 4, 2004, Pages 241-250

  Calza, Leonardo ^a   Manfredi, Roberto ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; EFAVIRENZ; FLUOXETINE; GESTAGEN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOCORTICOID; GLUCOSE; INDINAVIR; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGESTROL ACETATE; METFORMIN; NELFINAVIR; NEVIRAPINE; ORAL ANTIDIABETIC AGENT; PENTAMIDINE; PIOGLITAZONE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; VALPROIC ACID;

ATHEROSCLEROSIS; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART INFARCTION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID METABOLISM; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER METABOLISM; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS DISEASE; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 20544441960     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2004.2.241     Document Type: Review

References (59)

1. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17(Suppl 1):S141-S148.
2. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003;22:89-99.
3. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003;52:1695-1700.
4. Calza L, Manfredi R, Chiodo F. Dislypidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:10-14.
5. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother 2001;35:343-351.
6. Gelato MC. Insulin and carbohydrate dysregulation. Clin Infect Dis 2003;36(Suppl 2):S91-S95.
7. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-2505.
8. Walli R, Herfort O, Michl GM. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-infected patients. AIDS 1998;12:F167-F173.
9. Behrens G, Dejam A, Schmidt H. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.
10. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099.
11. Dube MMP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997;350:713-714.
12. Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med 1992;327:1360-1365.
13. Hommes MJT, Ramijn JA, Endert E. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infecetd men. Metabolism 1991;40:651-656.
14. Heylingenber R, Romijn JA, Hommes MJT. Non-insulin mediated glucose uptake in human immunodeficiency virus-infected men. Clin Sci 1993;84:209-216.
15. Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991;3:143-158.
16. Poli G, Fauci AS. The role of monocyte/macrophages and cytokines in the pathogenesis of HIV infection. Pathophysiology 1992;60:246-251.
17. Patton JS, Shepard HM, Wilking H. Interferons and tumor necrosis factor have similar catabolic effects on 3TC-L1 cells. Proc Natl Acad Sci U S A 1986;83: 8313-8317.
18. Grunfeld C, Kotler DP, Shigenaga JK. Circulating interpheron-alpha level and hypertriglyceridaemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-162.
19. Seale JP, Compton MR. Side-effects of corticosteroids agents. Med J Aust 1986;144:139-142.
20. Henry K, Rathgaber S, Sullivan C, McCabe K. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 1992; 116:53-54.
21. Shen M, Orwell ES, Cohn SE. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med 1989;86: 726-728.
22. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-2056.
23. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycaemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003;33:577-584.
24. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis 2003; 36:1318-1323.
25. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
26. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
27. Saint-Marc T, Poizot-Martin I, Partisani M. A syndrome of lipodystrophy in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13: 1659-1667.
28. Yarasheski KE, Tebas P, Sigmund C. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Syndr Hum Retrovirol 1999;21:209-216.
29. Andersen O, Haugaard SB, Andersen UB, Friis-Möller N, Storgaard H, Volund A, Nielsen JO, Iversen J, Madsbad S. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β-cell function. Metabolism 2003;52:1343-1353.
30. Jakob S, Machann J, Rett K. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic subjects. Diabetes 1999;48:1113-1119.
31. Perseghin G, Scifo P, De Corbelli F. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: A 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999;48:1600-1606.
32. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20521-20524.
33. Rudich A, Vanounou S, Riesenberg K, Porat M, Tirosh A, Harman-Boehm I, Greenberg AS, Schlaeffer F, Bashan N. The HIV protease inhibitor nelfinavir induces insulin resistance and increase basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001;50:1425-1431.
34. Bastard JP, Caron M, Vidal H. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-1031.
35. Brinkman K, Burger D, Smeitink JAM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744.
36. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-1115.
37. Garg A. Dyslipoproteinemia and diabetes. Endocrinol Metab Clin North Am 1998;27:613-625.
38. Mulligan K, Grunfeld C, Tai VW. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
39. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000;31:787-797.
40. Henry K, Melroe H, Huebsch J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
41. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999;131:548.
42. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-1959.
43. Friedl AC, Attenhofer Jost CH, Schalcher C. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 2000;14:2790-2792.
44. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group, Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349: 1993-2003.
45. Dever LL, Oruwari PA, Figueroa WE, O'Donovan CA, Eng RH. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother 2000;34:580-584.
46. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 2000;23(Suppl 1):S43-S46.
47. Summary of the second report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-3023.
48. Ruiz L, Negredo E, Domingo P. Antiretroviral treatment simplification with nevirapine in PI-experienced patients with HIV-associated lipodystrophy: one-year prospective follow-up of a multicentre, randomised, controlled study. J Acquir Immune Defic Syndr 2001; 27:229-236.
49. Opravil M, Hirschel B, Lazzarin A. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-1260.
50. Negredo E, Cruz L, Paredes R. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-510.
51. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999;13:1000-1002.
52. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-477.
53. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-4615.
54. Walli RK, Michl GM, Bogner JR, Brinkmann L, Goebel FD. Effects of the PPAR-activator troglitazone on protease inhibitor associated peripheral insulin resistance. in: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, (Chicago, January 31-February 4, 1999).
55. Gelato MC, Mynarcik DC, Quick JL. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002;31:163-170.
56. Sutinen J, Hakkinen AM, Westerbacka J. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199-207.
57. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamaki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Jarvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; Jan 28 [Epub ahead of print]
58. Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of type 2 diabetes. Expert Opin Pharmacother 2002;3:529-540.
59. Justman JE, Benning L, Danoff A. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003;32:298-302.